Status In progress
Process MTA
ID number 858

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Novartis (everolimus)
  Pfizer (sunitinib)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups The NET Patient Foundation
Professional groups British Institute of Radiology
  British Nuclear Medicine Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (CAU not returned, not participating)
  Allergan UK (CAU not returned, not participating)
  Hospira UK (CAU not returned, not participating)
  Janssen (CAU not returned, not participating)
  medac GmBH (CAU not returned, not participating)
  Merck Sharp and Dohme (CAU not returned, not participating)
  Novartis (octreotide long acting release)
  Pfizer (doxorubicin)
  Roche Products (CAU not returned, not participating)
  Sun Pharmaceuticals UK (CAU not returned, not participating)
  Teva Pharma (CAU not returned, not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
28 June 2017 Expected publication
14 June 2017 The scope for this technology appraisal included lutetium-177 dotatate (177Lu-dotatate). NICE cannot release any recommendations on 177Lu-dotatate until it has a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. A separate document with the committee’s recommendations will be released when this opinion is received. Information about this separate document can be found on the NICE website.
12 May 2017 - 26 May 2017 Final appraisal determination
28 February 2017 Committee meeting: 1
25 May 2016 Invitation to participate
22 February 2016 Draft scope documents
04 November 2015 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance